首页> 美国卫生研究院文献>Biotechnology Reports >Validation of a cell-based colorimetric reporter gene assay for the evaluation of Type I Interferons
【2h】

Validation of a cell-based colorimetric reporter gene assay for the evaluation of Type I Interferons

机译:基于细胞的比色报告基因测定法对I型干扰素评估的验证

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The biotherapeutic type I interferons (IFN-I) are indicated to treat several diseases. These products are regulated to guarantee safety and efficacy through critical quality attributes. For this purpose, the development of robust assays is required, followed by its validation to demonstrate their suitability for its intended purpose. Despite there are some commercial kits to evaluate IFN-I signaling, these are focused on measuring in vitro biological response instead of their validation, which is a pharmaceutical industry requirement. The aim of this work was to validate the HEK-Blue IFN-α/β system evaluating the biological activity of IFN-α/β under good laboratory practices, according to international standards. Our results demonstrated that HEK-Blue IFN-α/β system comply with accuracy (r2>0.95) precision (CV < 20%) and specificity for both IFN-α/β; confirming that this assay is robust for this biotherapeutics’ evaluation. Thereby, this bioassay could be implemented as a complementary method to the classical anti-proliferative and anti-viral assays under quality control environments.
机译:I型生物治疗干扰素(IFN-I)可治疗多种疾病。对这些产品进行监管,以通过关键的质量属性保证安全性和有效性。为此,需要开发鲁棒的测定方法,然后进行验证以证明其适用于其预期目的。尽管有一些用于评估IFN-1信号传导的商业试剂盒,但这些试剂盒侧重于测量体外生物学反应,而不是对其进行验证,这是制药行业的要求。这项工作的目的是根据国际标准,验证在良好实验室规范下评估IFN-α/β生物学活性的HEK-BlueIFN-α/β系统。我们的结果表明,HEK-BlueIFN-α/β系统符合准确度(r 2

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号